1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Non-Cutaneous Melanoma: new trials by email Literature Review of Recurrent Non-Cutaneous Melanoma trials Research Report on Recurrent Non-Cutaneous Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
Melanoma (1)
Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
CTLA-4 Antigen (1) · Interferon alpha-2 (1) · Introns (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · pembrolizumab (1)
National Cancer Institute (NCI) (1)
Canada (1) · Ireland (1) · United States (1)
Sapna Patel (1)
U10CA180888 (1)